Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. [electronic resource]
Producer: 20100901Description: 3485-94 p. digitalISSN:- 1557-3265
- Aged
- Aged, 80 and over
- Androstadienes -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antigens, CD -- immunology
- Antigens, Differentiation, T-Lymphocyte -- metabolism
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- CTLA-4 Antigen
- Drug Administration Schedule
- Female
- Humans
- Inducible T-Cell Co-Stimulator Protein
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms, Hormone-Dependent -- drug therapy
- T-Lymphocytes -- immunology
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.